Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Bettering distant management of lung most cancers is probably the most thrilling potential profit of mixing JNJ-1900 with Keytruda (pembrolizumab), defined by Dr....
Dr. Nausheen Ahmed critiques key 2025 ASCO findings in myeloma and lymphoma, together with new therapies and trials enhancing affected person choices and...
Sufferers with blood cancers like polycythemia vera, a form of myeloproliferative neoplasm, might profit in studying extra about latest information from ASCO 2025.Sufferers...
